Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208210 | 0.85 | CHRNB4 (0.36) | CHRNB4CHRNA3KDM4EMIFKIF11 | |
| SCHEMBL4641139 | 0.79 | CHRNB4 (0.37) | CHRNB4CHRNA3GAAMIF | |
| SCHEMBL2208302 | 0.78 | CHRNB4 (0.42) | CHRNB4CHRNA3SSTR5 | |
| SCHEMBL2206356 | 0.78 | CHRNB4 (0.39) | CHRNB4CHRNA3KDM4EMIFKIF11 | |
| SCHEMBL12434594 | 0.76 | CHRNB4 (0.37) | CHRNB4CHRNA3 | |
| SCHEMBL4640229 | 0.73 | CHRNB4 (0.42) | CHRNB4CHRNA3 | |
| SCHEMBL2210658 | 0.72 | CHRNB4 (0.36) | CHRNB4CHRNA3KDM4EMIFKIF11 | |
| SCHEMBL4643609 | 0.71 | NPC1 (0.34) | CHRNB4CHRNA3KDM4EGAANPC1 | |
| SCHEMBL16175483 | 0.71 | RAB9A (0.37) | CHRNB4CHRNA3KDM4EMIFNPC1 | |
| SCHEMBL2205238 | 0.70 | KDM4E (0.37) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | claimed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| US-7981883-B2 | Substituted spiro-compounds and the use thereof for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275628-A1 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | REN, PKD1, PKD2 | CHRNB4 4783/4885CHRNA3 4690/4885KDM4E 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.